T-group (topology)
12.1.1 Glycosyl hydrolase domain
Ligands and drugs
5,198
Member domains
1,195
with ligand contacts (≤ 4 Å)
23.0% of members
823
with DrugDomain annotations
15.8% of members
540
with a DrugBank compound
10.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 12.1.1 belongs to X-group 12 Glycosyl hydrolase domain-like, which binds 6.5 ligand superclasses per 20 proteins, narrower than 68% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 212 |
| DB03434 | MPO | 3-(N-morpholino)propanesulfonic acid | 13 |
| DB02379 | BGC | Beta-D-Glucose | 10 |
| DB05018 | DGJ | Migalastat | 9 |
| DB00139 | SIN | Succinic acid | 6 |
| DB00284 | — | — | 6 |
| DB09459 | TLA | L-tartaric acid | 6 |
| DB03142 | AHR | Alpha-L-Arabinose | 5 |
| DB00135 | TYR | Tyrosine | 2 |
| DB00491 | — | Miglitol | 2 |
| DB00747 | — | Scopolamine | 2 |
| DB01694 | TAR | D-tartaric acid | 2 |
| DB02218 | — | N-[4-hydroxymethyl-cyclohexan-6-yl-1,2,3-triol]-4,6-dideoxy-4-aminoglucopyranoside | 2 |
| DB03092 | HMC | 5-Hydroxymethyl-Chonduritol | 2 |
| DB04237 | TAM | Tris(Hydroxyethyl)Aminomethane | 2 |
| DB04878 | — | Voglibose | 2 |
| DB00130 | GLN | L-Glutamine | 1 |
| DB00156 | THR | Threonine | 1 |
| DB00160 | ALA | Alanine | 1 |
| DB01870 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 172 |
| NAmetal | SODIUM ION | 119 |
| CAmetal | CALCIUM ION | 73 |
| CL | CHLORIDE ION | 36 |
| MGmetal | MAGNESIUM ION | 23 |
| C2E | 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one) | 13 |
| IOD | IODIDE ION | 13 |
| MPO | 3[N-MORPHOLINO]PROPANE SULFONIC ACID | 13 |
| GLC | alpha-D-glucopyranose | 11 |
| P6G | HEXAETHYLENE GLYCOL | 10 |
| DGJ | (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol | 9 |
| GAL | beta-D-galactopyranose | 9 |
| N0K | 5-[ethyl(methyl)amino]-~{N}-[6-[[(1~{S},2~{R},3~{S},4~{R})-2-(hydroxymethyl)-3,4-bis(oxidanyl)cyclopentyl]amino]hexyl]naphthalene-1-sulfonamide | 8 |
| N0N | 5-(dimethylamino)-~{N}-[6-[[(1~{R},2~{R},3~{S},4~{S},5~{S})-2-(hydroxymethyl)-3,4,5-tris(oxidanyl)cyclopentyl]amino]hexyl]naphthalene-1-sulfonamide | 8 |
| N0Q | 5-(dimethylamino)-~{N}-[6-[(2~{R},3~{R},4~{S},5~{R})-3-(hydroxymethyl)-4,5-bis(oxidanyl)piperidin-2-yl]hexyl]naphthalene-1-sulfonamide | 8 |
| N0T | (1~{S},2~{S},3~{S},4~{R},5~{R})-4-(hydroxymethyl)-5-(octylamino)cyclopentane-1,2,3-triol | 8 |
| N0W | 5-(dimethylamino)-~{N}-[6-[(2~{S},3~{R},4~{S},5~{R})-3-(hydroxymethyl)-4,5-bis(oxidanyl)piperidin-2-yl]hexyl]naphthalene-1-sulfonamide | 8 |
| N8V | (1S,2S,3S,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol | 8 |
| YGX | (1~{S},2~{S},4~{S},5~{R})-6-(hydroxymethyl)cyclohexane-1,2,3,4,5-pentol | 8 |
| TLA | L(+)-TARTARIC ACID | 7 |